- Strong Net Income: Tigermed reported a net income of 492.8 million yuan for the first half of the year.
- Impressive Revenue: The company achieved a revenue of 3.36 billion yuan during the same period.
- Earnings Per Share: Tigermed’s earnings per share (EPS) were recorded at 57 RMB cents.
- Analyst Recommendations: The stock has attracted 21 buy recommendations, 5 hold recommendations, and 3 sell recommendations.
A look at Hangzhou Tigermed Consulting (A) Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Hangzhou Tigermed Consulting Company Limited, a provider of professional clinical research services, presents a solid long-term outlook based on its Smartkarma Smart Scores. With consistent scores of 3 in Value, Dividend, and Growth, and higher ratings of 4 in Resilience and Momentum, the company displays a balanced profile. Its services cater to both domestic and foreign pharmaceutical and health-related research, emphasizing clinical trial technology, data management, and statistical analysis. This diverse range of services positions Hangzhou Tigermed Consulting (A) to sustain growth and resilience in the industry.
In summary, Hangzhou Tigermed Consulting (A) has been recognized for its robust performance across various aspects according to the Smartkarma Smart Scores. With a strong focus on clinical research services for pharmaceutical and health-related development, the company maintains a stable outlook for long-term success. Its consistent ratings in Value, Dividend, Growth, Resilience, and Momentum underscore its potential to thrive in the competitive landscape of clinical research and analysis.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
